FogPharma

About:

FogPharma is a biopharmaceutical firm that develops precision medicines for the vast majority of therapeutic targets.

Website: http://www.fogpharma.com

Top Investors: General Catalyst, Google Ventures, Fidelity, Deerfield, ARCH Venture Partners

Description:

FogPharma was born from the scientific and entrepreneurial vision of founder Greg Verdine, a pioneer in the discovery and development of new drug classes that “drug the undruggable.” FogPharma’s cell-penetrating mini proteins (CPMPs) are a broad new class of medicines that can drug targets beyond the reach of conventional therapeutics. Together with world-leading experts and collaborators in cancer biology and therapy, our team is building a drug discovery powerhouse having passion, knowledge, and creativity to develop fundamentally new cancer treatments. FogPharma derives financial support from a unique syndicate of extraordinary private and institutional investors. FogPharma’s network of friends includes our founders, employees, investors, advisors, collaborators, and cancer patients; all working together to pioneer a unique approach toward conquering cancer. It is laser-focused and unstoppable in its mission to deliver a new class of medicines to patients and their families to bring them years to life and life to years.

Total Funding Amount:

$530M

Estimated Revenue Range:

$1M to $10M

Headquarters Location:

Cambridge, Massachusetts, United States

Founded Date:

2015-01-01

Contact Email:

info(AT)fogpharma.com

Founders:

Greg Verdine, John McGee, Sir David Lane, Weiqing Zhou

Number of Employees:

101-250

Last Funding Date:

2024-03-01

IPO Status:

Private

© 2025 bioDAO.ai